These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 21122628)

  • 1. Subjects with elevated LDL cholesterol and metabolic syndrome benefit from supplementation with soy protein, phytosterols, hops rho iso-alpha acids, and Acacia nilotica proanthocyanidins.
    Lerman RH; Minich DM; Darland G; Lamb JJ; Chang JL; Hsi A; Bland JS; Tripp ML
    J Clin Lipidol; 2010; 4(1):59-68. PubMed ID: 21122628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Mediterranean-style, low-glycemic-load diet decreases atherogenic lipoproteins and reduces lipoprotein (a) and oxidized low-density lipoprotein in women with metabolic syndrome.
    Jones JL; Comperatore M; Barona J; Calle MC; Andersen C; McIntosh M; Najm W; Lerman RH; Fernandez ML
    Metabolism; 2012 Mar; 61(3):366-72. PubMed ID: 21944261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of a low glycemic index diet with soy protein and phytosterols on CVD risk factors in postmenopausal women.
    Lukaczer D; Liska DJ; Lerman RH; Darland G; Schiltz B; Tripp M; Bland JS
    Nutrition; 2006 Feb; 22(2):104-13. PubMed ID: 16459222
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dietary plant sterols supplementation does not alter lipoprotein kinetics in men with the metabolic syndrome.
    Ooi EM; Watts GF; Barrett PH; Chan DC; Clifton PM; Ji J; Nestel PJ
    Asia Pac J Clin Nutr; 2007; 16(4):624-31. PubMed ID: 18042521
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Low intestinal cholesterol absorption is associated with a reduced efficacy of phytosterol esters as hypolipemic agents in patients with metabolic syndrome.
    Hernández-Mijares A; Bañuls C; Jover A; Solá E; Bellod L; Martínez-Triguero ML; Lagarda MJ; Víctor VM; Rocha M
    Clin Nutr; 2011 Oct; 30(5):604-9. PubMed ID: 21489663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Low-density lipoprotein cholesterol reduction and goal achievement with ezetimibe/simvastatin versus atorvastatin or rosuvastatin in patients with diabetes, metabolic syndrome, or neither disease, stratified by National Cholesterol Education Program risk category.
    Polis AB; Abate N; Catapano AL; Ballantyne CM; Davidson MH; Smugar SS; Tershakovec AM
    Metab Syndr Relat Disord; 2009 Dec; 7(6):601-10. PubMed ID: 19929597
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of atorvastatin in achieving National Cholesterol Education Program low-density lipoprotein targets in women with severe dyslipidemia and cardiovascular disease or risk factors for cardiovascular disease: The Women's Atorvastatin Trial on Cholesterol (WATCH).
    McPherson R; Angus C; Murray P; Genest J;
    Am Heart J; 2001 Jun; 141(6):949-56. PubMed ID: 11376309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of substituting dietary soybean protein and oil for milk protein and fat in subjects with hypercholesterolemia.
    Kurowska EM; Jordan J; Spence JD; Wetmore S; Piché LA; Radzikowski M; Dandona P; Carroll KK
    Clin Invest Med; 1997 Jun; 20(3):162-70. PubMed ID: 9189647
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of soy supplementation on blood lipids and arterial function in hypercholesterolaemic subjects.
    Hermansen K; Hansen B; Jacobsen R; Clausen P; Dalgaard M; Dinesen B; Holst JJ; Pedersen E; Astrup A
    Eur J Clin Nutr; 2005 Jul; 59(7):843-50. PubMed ID: 15900307
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revised Adult Treatment Panel III guidelines and cardiovascular disease mortality in men attending a preventive medical clinic.
    Ardern CI; Katzmarzyk PT; Janssen I; Church TS; Blair SN
    Circulation; 2005 Sep; 112(10):1478-85. PubMed ID: 16129792
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Apolipoprotein B and non-high-density lipoprotein cholesterol are better risk markers for coronary artery disease than low-density lipoprotein cholesterol in hypertriglyceridemic metabolic syndrome patients.
    Boumaiza I; Omezzine A; Rejeb J; Rebhi L; Kalboussi N; Ben Rejeb N; Nabli N; Ben Abdelaziz A; Boughazala E; Bouslama A
    Metab Syndr Relat Disord; 2010 Dec; 8(6):515-22. PubMed ID: 20715933
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of a dietary portfolio diet of cholesterol-lowering foods and a statin on LDL particle size phenotype in hypercholesterolaemic participants.
    Gigleux I; Jenkins DJ; Kendall CW; Marchie A; Faulkner DA; Wong JM; de Souza R; Emam A; Parker TL; Trautwein EA; Lapsley KG; Connelly PW; Lamarche B
    Br J Nutr; 2007 Dec; 98(6):1229-36. PubMed ID: 17663803
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A meta-analysis of the effect of soy protein supplementation on serum lipids.
    Reynolds K; Chin A; Lees KA; Nguyen A; Bujnowski D; He J
    Am J Cardiol; 2006 Sep; 98(5):633-40. PubMed ID: 16923451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increased small low-density lipoprotein particle number: a prominent feature of the metabolic syndrome in the Framingham Heart Study.
    Kathiresan S; Otvos JD; Sullivan LM; Keyes MJ; Schaefer EJ; Wilson PW; D'Agostino RB; Vasan RS; Robins SJ
    Circulation; 2006 Jan; 113(1):20-9. PubMed ID: 16380547
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma markers of cholesterol homeostasis and apolipoprotein B-100 kinetics in the metabolic syndrome.
    Chan DC; Watts GF; Barrett PH; O'Neill FH; Thompson GR
    Obes Res; 2003 Apr; 11(4):591-6. PubMed ID: 12690090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of margarines and butter consumption on lipid profiles, inflammation markers and lipid transfer to HDL particles in free-living subjects with the metabolic syndrome.
    Gagliardi AC; Maranhão RC; de Sousa HP; Schaefer EJ; Santos RD
    Eur J Clin Nutr; 2010 Oct; 64(10):1141-9. PubMed ID: 20648041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cholesteryl ester transfer protein in metabolic syndrome.
    Sandhofer A; Kaser S; Ritsch A; Laimer M; Engl J; Paulweber B; Patsch JR; Ebenbichler CF
    Obesity (Silver Spring); 2006 May; 14(5):812-8. PubMed ID: 16855190
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: rationale and design of the JUPITER trial.
    Ridker PM;
    Circulation; 2003 Nov; 108(19):2292-7. PubMed ID: 14609996
    [No Abstract]   [Full Text] [Related]  

  • 19. Increased apolipoprotein E level and reduced high-density lipoprotein mean particle size associate with low high-density lipoprotein cholesterol and features of metabolic syndrome.
    Söderlund S; Watanabe H; Ehnholm C; Jauhiainen M; Taskinen MR
    Metabolism; 2010 Oct; 59(10):1502-9. PubMed ID: 20206948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Frequency of metabolic syndrome among hemodialysis patients according to NCEP-ATP III and IDF definitions.
    Ucar E; Huzmeli C; Guven O; Savas N; Gullu M; Asilyoruk S; Kuvandik C; Temizkan A; Kuvandik G
    Ren Fail; 2009; 31(3):221-8. PubMed ID: 19288328
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.